Ivey Business School (Canada)
-
Dr. Reddy's Laboratories (B)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08M065-EStrategyThis supplement to Dr. Reddy's Laboratories (A), product # 9B08M064, looks at the two years post-acquisition and examines a major risk which, as it unfolded, brought the viability of the business model into question.Starting at €5.74
-
Dr. Reddy's Laboratories (A)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08M064-EStrategyDr. Reddy's Laboratories (Dr. Reddy's), a large pharmaceutical company in India, is trying to acquire the fourth largest generics manufacturer in Germany. Dr. Reddy's quoted $570 million in a competitive bidding situation. The company's chief negotiator is getting ready to close the deal if selected. Students will examine the issues for the chief negotiator, such as: is the price right, is the fit strategic, will the acquisition add value, how ca...Starting at €8.20
-
Boehringer Ingelheim: Leading Innovation
J. Robert Mitchell; Ramasastry ChandrasekharCase IVEY-9B14M168-EEntrepreneurship, StrategyThe newly appointed director of Innovation Management & Strategy at Boehringer Ingelheim, a German-based multinational pharmaceutical company, is finding his way forward in his firm’s new, first-of-its-kind role, which is central to the company’s growth rejuvenation strategy. His job has a threefold mandate: to build internal networks, to establish internal structures and to leverage internal ideas. His biggest challenge, however, may be transfor...Starting at €8.20
-
Project Have Hope: Managing Growth, Commitment, Time, Inventory, and Other Challenges
Nardia Haigh; Jamila Gilliam; Frank SmithCase IVEY-9B20M011-EEntrepreneurship, StrategyBoston-based Project Have Hope was a non-profit social enterprise promoting financial stability for 100 women in Kampala, Uganda, who had been displaced as a result of Uganda’s civil war. Established in 2006, Project Have Hope used revenue from the sale of paper bead jewellery and other products made by the women to provide training, loans, and children’s tuition. The project faced many challenges over the years, including an unplanned expansion ...Starting at €8.20
-
SafeMotos: Scaling up Innovations in African Ride Hailing
Darren Meister; Ramasastry ChandrasekharCase IVEY-9B20M182-EEntrepreneurship, StrategyIn April 2018, the two co-founders of SafeMotos, a motorcycle taxi service in Rwanda, in Central Africa, were examining their expansion plan. Their start-up had not yet become profitable, but they were already making plans to expand into the neighbouringStarting at €8.20
-
Volkswagen Strategy 2025: Shifting Gears in Disruptive Times
Andreas Schotter; Thomas Watson; Ramasastry ChandrasekharCase IVEY-9B19M047-EStrategyIn 2018, Volkswagen Group’s newly appointed chief executive officer renewed the company’s commitment to Strategy 2025, an ongoing plan intended to radically transform the German automaker. Volkswagen was being challenged by tectonic changes in the automotive industry, including the phasing out of the long-standing internal combustion engine, ongoing digitization, the entry of new competition from technology companies, the introduction of electric...Starting at €8.20
-
Dr. Reddy's Laboratories (A) (Spanish version)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08MS64StrategyDr. Reddy's Laboratories (Dr. Reddy's), a large pharmaceutical company in India, is trying to acquire the fourth largest generics manufacturer in Germany. Dr. Reddy's quoted $570 million in a competitive bidding situation. The company's chief negotiator is getting ready to close the deal if selected. Students will examine the issues for the chief negotiator, such as: is the price right, is the fit strategic, will the acquisition add value, how ca...Starting at €8.20
-
Dr. Reddy's Laboratories (B) (Spanish version)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08MS65StrategyThis supplement to Dr. Reddy's Laboratories (A), product # 9B08M064, looks at the two years post-acquisition and examines a major risk which, as it unfolded, brought the viability of the business model into question.Starting at €5.74